Nexus Dx

May 22, 2018 – Hennigsdorf/San Diego – German diagnostics company sphingotec GmbH (Hennigsdorf) and Nexus Dx (San Diego) have combined their technology platforms to market sphingotec’s CE-marked acute biomarkers penKid® and bio-ADM® on Nexus’ market-validated POC testing immunoassay platform IB10 to substantially improve decision-making in emergency departments (EDs) and intensive care units (ICUs).

Cookie Preference

Please select an option. You can find more information about the consequences of your choice at Help. Privacy Policy | Imprint

Select an option to continue

Your selection was saved!

More information

Help

To continue, you must make a cookie selection. Below is an explanation of the different options and their meaning.

  • Accept all cookies:
    All cookies such as tracking and analytics cookies.
  • Accept first-party cookies only:
    Only cookies from this website.
  • Reject all cookies:
    No cookies except for those necessary for technical reasons are set. Borlabs Cookie already set a necessary cookie.

You can change your cookie setting here anytime: Privacy Policy. Imprint

Back

Top